Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6321 |
Tofacitinib
托法替尼,Tasocitinib,CP-690550 |
ROCK; Apoptosis; JAK; Src | Angiogenesis; Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Cytoskeletal Signaling; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
Tofacitinib (Tasocitinib) 是口服小分子 Janus 激酶抑制剂,用于治疗中度至重度类风湿性关节炎。 | |||
T13427 |
(3S,4R)-Tofacitinib
|
Others | Others |
(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM). | |||
T2398 |
Tofacitinib Citrate
CP-690550 citrate,柠檬酸托法替尼,枸橼酸托法替尼,Tasocitinib citrate,Tofacitinib (CP-690550) Citrate |
Apoptosis; Influenza Virus; JAK; Antibacterial; Antifungal | Angiogenesis; Apoptosis; Chromatin/Epigenetic; JAK/STAT signaling; Microbiology/Virology; Stem Cells |
Tofacitinib Citrate (CP-690550 citrate) 是 JAK1/2/3抑制剂,IC50分别为112,20 和 1 nM。它具有抗菌,抗真菌和抗病毒活性。 | |||
T69958 |
Tofacitinib maleate
|
||
Tofacitinib maleate, also known as tasocitinib, CP-690550, is a Janus kinase (JAK) inhibitor. Tofacitinib maleate modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signaling through pairing of JAKs (e.g., JAK1/JAK3, JAK1/JAK2, JAK1/TyK2, JAK2/JAK2). Tofacitinib maleate inhibited the in vitro activities of JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 combinations with IC50 of 406, 56, and 1377 nM, respectively. |